
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra Inc. demonstrated strong growth in its Thrombectomy segment, achieving record procedure volumes in December and an impressive year-over-year sales increase of 16.9%, contributing to a total of $222.7 million. Concurrently, the company's non-GAAP operating margins improved significantly, with a 200 basis point increase year-over-year due to enhanced gross margins—up 170 basis points to 67.4%—and reduced R&D expenses. The overall financial performance, highlighted by continued market share gains and improved productivity, positions Penumbra favorably within the medical device industry.
Bears say
The financial outlook for Penumbra Inc is increasingly negative, with projections indicating a decline in revenue growth to less than 12%, primarily due to underwhelming contributions from new products and slower-than-expected profitability improvements. There are significant risks identified, including competition leading to market share loss, delayed product clearances, and potential disruptions from supply chain issues, which compound the already lowered revenue estimates for 2025 and 2026. Furthermore, the international market presents challenges, particularly in China, while only partially benefiting from the introduction of CAVT products in Europe.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares